Morgan Stanley Cuts XP to $19 as Stock Trades Below Target
Morgan Stanley downgraded XP Inc. to Equalweight with a $19 target on October 29, but the stock was already trading at $14.29. The divergence with analyst consensus of $25.65 suggests either Brazilian
Morgan Stanley Cuts XP Inc. to Equalweight, Target $19
NEW YORK, November 2 —
Morgan Stanley's Equalweight call on XP Inc. (XP), published October 29 with a $19 price target, landed after the stock had already traded through that level; XP was at $14.29 when the downgrade was issued. Whether that gap shows value or proof that analyst models are still catching up is the question the next earnings report must answer.
- XP trades at $14.29, 44% below the $25.65 consensus analyst price target as of October 29, 2026.
- A director sold $2.41 million of XP shares at $19.58 on September 16, six days after an equity prospectus filing.
- XP beat consensus EPS in three of its last four quarters; TTM revenue of $18.63 billion grew 10.6% year-over-year.
When the Downgrade Is Already Priced
Morgan Stanley's $19 target now sits 33% above where XP trades. The remaining analyst consensus, at a mean price target of $25.65, implies more than 79% upside from current levels; the divergence leaves two explanations: Brazil-specific macro risk has shifted faster than models allow, or the broader analyst community needs to revise down. XP runs Brazil's largest open investment platform, brokerage, fixed income, derivatives, mutual funds, insurance, and credit, with trailing revenue of $18.63 billion growing 10.6% year-over-year and a 69.2% gross margin. Investors can stress-test the implied assumptions at the DCF calculator.
The Director Sold Above the Downgrade Target
Six days after XP filed a 424B7 prospectus supplement on September 10, director Dos Santos Bruno Constantino Alexandre sold 123,257 shares on the open market at $19.58 per share for approximately $2.41 million. No insider purchases appear in the 90-day window; the net insider position is entirely one-sided. That exit price clears Morgan Stanley's stated downgrade target issued six weeks later, meaning the director received a price that the Street's most bearish voice now considers fair value.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| XP | $7.3B | 5.8x | -22.1% |
| PAGS | $2.2B | 4.2x | -16.1% |
| ITUB | $78.6B | 7.4x | -1.7% |
| SUZ | $11.4B | 6.2x | +2.1% |
| INTR | $1.8B | 4.3x | -57.2% |
| PGNY | $2.2B | 12.6x | +58.4% |
What the Next Print Must Show
XP beat consensus EPS estimates in three of its last four reported quarters, posting surprises of 2.1%, 2.4%, and 1.9% before a 1.6% miss. Whether the next print extends that pattern is the nearest observable data point for investors weighing whether analyst targets reflect stale optimism or real fair value. The structural question is larger: a 69.2% gross margin business with 84.1% institutional ownership trading at a 44% discount to consensus target is either a delayed repricing of Brazil macro risk or proof that the analyst community is lagging the market. Run the free XP Inc. deep-dive → for the current snapshot.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
What was Morgan Stanley's downgrade of XP Inc.?
Morgan Stanley downgraded XP Inc. to Equalweight with a $19 price target on October 29, 2026. The stock was trading at $14.29 when the downgrade was issued, 44% below the consensus analyst price target of $25.65.
What is the analyst consensus price target for XP Inc.?
Analyst consensus projects a mean price target of $25.65 for XP Inc., implying 79% upside from the $14.29 trading level. Morgan Stanley's $19 target sits 33% above the current stock price.
What does XP Inc. do?
XP Inc. operates Brazil's broadest open investment platform, offering brokerage, fixed income, derivatives, mutual funds, insurance, and credit services. The company has trailing revenue of $18.63 billion growing 10.6% year-over-year with a 69.2% gross margin.
Has XP Inc. beaten earnings estimates?
XP beat consensus EPS estimates in three of its last four reported quarters, posting surprises of 2.1%, 2.4%, and 1.9%. The company recorded a 1.6% miss in the most recent quarter.
When did an XP director sell shares?
A director sold 123,257 shares on September 16 at $19.58 per share for approximately $2.41 million. This was six days after XP filed a prospectus supplement, and notably at a price above Morgan Stanley's $19 downgrade target issued six weeks later.
Morgan Stanley downgraded XP Inc. to Equalweight on October 29 with a price target of $19 — yet XP already trades at $14.29, well below even that reduced target. The article must answer whether the selloff has already priced in more pain than the most pessimistic major analyst can justify.
Sources & Filings